Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stem Cell Dose to Reduce Symptom Burden in Multiple Myeloma and Amyloidosis
NCT00651937Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2008
- Primary completion
- Jan 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous hematopoietic stem cells in multiple myeloma (MM), AL amyloidosis (AL), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2008; status: completed.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
multiple myeloma (MM)AL amyloidosis (AL)
Beyond the preview
Go deeper on NCT00651937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00651937.